- Home
- ABOS vs AVTX Comparison
ABOS vs AVTX Comparison
Compare ABOS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- AVTX
- Stock Information
- Founded
- ABOS 1996
- AVTX 2011
- Country
- ABOS United States
- AVTX United States
- Employees
- ABOS N/A
- AVTX N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- AVTX Health Care
- Exchange
- ABOS Nasdaq
- AVTX Nasdaq
- Market Cap
- ABOS 66.6M
- AVTX 57.4M
- IPO Year
- ABOS 2021
- AVTX 2015
- Fundamental
- Price
- ABOS $1.00
- AVTX $4.35
- Analyst Decision
- ABOS Strong Buy
- AVTX Strong Buy
- Analyst Count
- ABOS 3
- AVTX 6
- Target Price
- ABOS $7.33
- AVTX $34.20
- AVG Volume (30 Days)
- ABOS 213.2K
- AVTX 67.7K
- Earning Date
- ABOS 05-13-2025
- AVTX 05-20-2025
- Dividend Yield
- ABOS N/A
- AVTX N/A
- EPS Growth
- ABOS N/A
- AVTX N/A
- EPS
- ABOS N/A
- AVTX N/A
- Revenue
- ABOS N/A
- AVTX $441,000.00
- Revenue This Year
- ABOS N/A
- AVTX N/A
- Revenue Next Year
- ABOS N/A
- AVTX N/A
- P/E Ratio
- ABOS N/A
- AVTX N/A
- Revenue Growth
- ABOS N/A
- AVTX N/A
- 52 Week Low
- ABOS $0.86
- AVTX $4.15
- 52 Week High
- ABOS $3.92
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- ABOS 44.19
- AVTX 32.20
- Support Level
- ABOS $1.00
- AVTX $4.80
- Resistance Level
- ABOS $1.13
- AVTX $5.26
- Average True Range (ATR)
- ABOS 0.10
- AVTX 0.47
- MACD
- ABOS 0.00
- AVTX 0.05
- Stochastic Oscillator
- ABOS 48.33
- AVTX 15.15
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).